516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial

• Andrés Cervantes,
• Victor Moreno,
• Maria Jure-Kunkel,
• Suresh Ramalingam,
• Emiliano Calvo,
• Patricia LoRusso,
• Brandon Higgs,
• Suzana Couto,
• Nora Pencheva,
• Santiago Ponce Aix,
• Daniel Cho,
• Alexander Muik,
• Özlem Türeci,
• Tahamtan Ahmadi,
• Ugur Sahin,
• Elena Garralda,
• Ulf Forssmann,
• Eleni Lagkadinou,
• José Trigo Pérez,
• Muhammad Furqan

Affiliations

Andrés Cervantes

Department of Medical Oncology, Hospital Clinico Universitario of Valencia, Biomedical Research Institute INCLIVA, CIBERONC and University of Valencia, Valencia, Spain

Victor Moreno

Cancer Prevention and Control Program, Catalan Institute of Oncology - IDIBELL, L`Hospitalet de Llobregat, Barcelona, Spain

Maria Jure-Kunkel

2Genmab A/S, Utrecht, Netherlands

Suresh Ramalingam

Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA

Emiliano Calvo

4START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

Patricia LoRusso

Department of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA

Brandon Higgs

Aff2 grid.418152.bMedImmune Gaithersburg MD USA

Suzana Couto

Genmab, Princeton, NJ, USA

Nora Pencheva

Genmab, Princeton, NJ, USA

Santiago Ponce Aix

2Medical Oncology, Sevilla, Spain

Daniel Cho

11NYU Medical Oncology Associates, New York, NY, USA

Alexander Muik

1BioNTech SE, Mainz, Germany

Özlem Türeci

1BioNTech SE, Mainz, Germany

Tahamtan Ahmadi

2Genmab A/S, Utrecht, Netherlands

Ugur Sahin

1BioNTech SE, Mainz, Germany

Elena Garralda

6Vall d’Hebron Institute of Oncology, Barcelona, Spain

Ulf Forssmann

8Genmab A/S, Princeton, NJ, USA

Eleni Lagkadinou

6BioNTech SE, Mainz, Germany

José Trigo Pérez

7Hospital Universitario Virgen de la Victoria, Málaga, Spain

Muhammad Furqan

9University of Iowa, Iowa City, USA